Opdivo demonstrates clinical activity in MSI-H colorectal cancer as a monotherapy and in combination with Yervoy.
By Dustin Phan, Analyst
23 May 2016
I am an analyst at Datamonitor Healthcare based in the San Diego – California office, where I am currently a member of...
Read full bio
Bristol-Myers Squibb has been actively investigating the combination of Opdivo and Yervoy in other solid tumor indications following its approval in melanoma, and the company has now released the first of such data for this regimen in colorectal cancer. In the CheckMate 142 trial, colorectal cancer patients with high microsatellite instability (MSI-H) tumors displayed impressive improvements in four-month progression free survival (PFS) rate and five-month overall survival (OS) rate when treated with both Opdivo and Yervoy compared to treatment with Opdivo monotherapy. If approved, Opdivo plus Yervoy would likely be limited to the MSI-H CRC patient population where the combination would compete with Keytruda. A separate early-phase trial testing Keytruda as monotherapy in MSI-H colorectal cancer resulted in an ORR of 62%, much higher than the 27% exhibited by patients receiving Opdivo monotherapy or the 15% exhibited by those on Opdivo plus Yervoy in CheckMate 142. Nonetheless, these early-phase data are limited in scope, and cross-trial assessments are incapable of presenting an accurate comparison at this stage. Larger trials with active comparators will be necessary to better evaluate the therapeutic potential of this combination.
Opdivo vs Opdivo plus Yervoy in MSI-H colorectal cancer – Interim results of CheckMate 142
|Treatment||Opdivo||Opdivo + Yervoy|
|Median PFS||5.3 months||N/A|
|4-month PFS rate||55%||80%|
|Median OS||16.3 months||N/A|
|5-month OS rate||75%||100%|
|ORR = overall response rate; OS = overall survival; PFS = progression free survivalSource: Datamonitor Healthcare, 2016; Biomedtracker, 2016|
Abstracts from the 52nd Annual meeting of the American Society of Clinical Oncology (ASCO) were released May 18th. Datamonitor Healthcare and Biomedtracker’s Pre-ASCO 2016 Report provides supplemental analyses on key abstracts and companies to watch during this year’s meeting.
Get your free demo today – simply fill out the form to the right.